Premium
Mutated cytochrome b as a determinant of a new monoclonal antibody (H8.98) on renal carcinoma cell lines recognized by a Vγ3Vδ1 + T‐cell clone
Author(s) -
Choudhary Anita,
Kurt Robert A.,
Goret Françoise,
Moreau Anne,
Diéz Elisabeth,
Urba Walter J.,
Jotereau Francine,
Pourcel Christine
Publication year - 1999
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19990812)82:4<562::aid-ijc15>3.0.co;2-w
Subject(s) - clone (java method) , monoclonal antibody , microbiology and biotechnology , monoclonal , biology , cell culture , renal cell carcinoma , complementary dna , virology , antibody , cancer research , medicine , immunology , pathology , gene , genetics
We generated a monoclonal antibody (MAb), H8.98, that recognizes an antigen shared by 50% of examined renal carcinoma cell (RCC) lines and is susceptible to lysis by a Vγ3Vδ1 + T‐cell clone derived from RCC tumor‐infiltrating lymphocytes. H8.98 inhibited Vγ3Vδ1 + T‐cell clone–mediated lysis of RCC lines. It did not stain normal kidney lines, melanomas, fibroblasts, Burkitt's lymphoma or Epstein‐Barr virus–transformed B‐cell lines but it did stain 2 of 4 tested breast cancer lines. Through screening of a renal carcinoma cDNA library using H8.98, we isolated a cDNA clone which, upon sequencing, was found to be cytochrome b with 2 point mutations. Int. J. Cancer 82:562–568, 1999. © 1999 Wiley‐Liss, Inc.